Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

CM Rudin, S Durinck, EW Stawiski, JT Poirier… - Nature …, 2012 - nature.com
CM Rudin, S Durinck, EW Stawiski, JT Poirier, Z Modrusan, DS Shames, EA Bergbower…
Nature genetics, 2012nature.com
Small-cell lung cancer (SCLC) is an exceptionally aggressive disease with poor prognosis.
Here, we obtained exome, transcriptome and copy-number alteration data from
approximately 53 samples consisting of 36 primary human SCLC and normal tissue pairs
and 17 matched SCLC and lymphoblastoid cell lines. We also obtained data for 4 primary
tumors and 23 SCLC cell lines. We identified 22 significantly mutated genes in SCLC,
including genes encoding kinases, G protein–coupled receptors and chromatin-modifying …
Abstract
Small-cell lung cancer (SCLC) is an exceptionally aggressive disease with poor prognosis. Here, we obtained exome, transcriptome and copy-number alteration data from approximately 53 samples consisting of 36 primary human SCLC and normal tissue pairs and 17 matched SCLC and lymphoblastoid cell lines. We also obtained data for 4 primary tumors and 23 SCLC cell lines. We identified 22 significantly mutated genes in SCLC, including genes encoding kinases, G protein–coupled receptors and chromatin-modifying proteins. We found that several members of the SOX family of genes were mutated in SCLC. We also found SOX2 amplification in ∼27% of the samples. Suppression of SOX2 using shRNAs blocked proliferation of SOX2-amplified SCLC lines. RNA sequencing identified multiple fusion transcripts and a recurrent RLF-MYCL1 fusion. Silencing of MYCL1 in SCLC cell lines that had the RLF-MYCL1 fusion decreased cell proliferation. These data provide an in-depth view of the spectrum of genomic alterations in SCLC and identify several potential targets for therapeutic intervention.
nature.com